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doi:10.1016/j.jtcvs.2006.05.035bjective: Surface-modified cardiopulmonary bypass circuits have been shown to
mprove platelet function and decrease postoperative bleeding after heart surgery in
dults. Two surface-modified cardiopulmonary bypass circuits are approved and
ommercially available for pediatric cardiac surgery. There have been few studies
emonstrating the efficacy of these modifications for children. We performed a
rospective, randomized trial comparing surface-modified cardiopulmonary bypass
ircuits to a standard unmodified circuit in pediatric cardiac surgery.
ethods: Sixty-nine children (median 6 months old) undergoing first-time cardiac
urgery were enrolled and randomized to an uncoated circuit or one of the two
ommercially available surface modified circuits for their operation. Blood samples
ere collected at baseline, on cardiopulmonary bypass, at the end of rewarming, after
rotamine, and at 18 to 24 postoperative hours. Platelet count, -thromboglobulin, and
hromboelastography with and without abciximab were measured. Postoperative chest
ube outputs and blood product utilization were also analyzed.
esults: The platelet counts, -thromboglobulin levels, thromboelastographic measures
f platelet function, and postoperative bleeding were not significantly different between
he surface-modified cardiopulmonary bypass circuit groups and the control group.
onclusion: Currently available surface-modified cardiopulmonary bypass circuits
o not significantly improve platelet function or clinical outcomes after routine
ediatric cardiac surgery.
he use of cardiopulmonary bypass (CPB) during cardiac surgery results in
damage to both the cellular and humoral components of the coagulation
system. This multifactorial process includes platelet activation and protein
enaturation at the blood-surface interface, hemodilution, and activation of the
 brinolytic pathways.1,2 Pediatric patients are at particular risk for postoperative co-
gulopathy because of the increased hemodilution inherent in pediatric CPB, the
elatively higher ratio of CPB circuit internal surface area to patient blood volume,
nd such preexisting patient factors as chronic cyanosis and polycythemia, which
re more common in patients with congenital heart disease.
Modification of the blood-contacting surfaces in CPB circuits has been shown to
mprove platelet number and function,3-5 decrease fibrinolysis,3,5 and decrease th
nflammatory response6 after cardiac surgery in adults. There are two surface-mod
PB (SM-CPB) circuits widely available for pediatric patients: the PMEA circui
hich incorporates an amphiphilic polymer coating (poly-2-methoxyethylacrylate)
n the blood-contacting surfaces of the tubing and oxygenator (Terumo Corpora-
ion, Tokyo, Japan), and the SMART circuit, which includes a combination of
hosphorylcholine coating with polycaprolactone-polydimethylsiloxilane additives
o the base polymer resin (COBE Cardiovascular, Inc, Arvada, Colo). These
M-CPB circuits have been tested extensively in adult patients, but there are few
The Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 3 675
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Data available documenting their efficacy for the pediatric
atient population. This prospective randomized trial was
esigned to compare the pediatric PMEA and SMART
M-CPB circuits against a standard unmodified circuit with
egard to platelet number, platelet function, and clinical
utcome.
atients and Methods
his study was reviewed and approved by the Emory University
chool of Medicine and Children’s Healthcare of Atlanta institu-
ional review boards, with informed consent obtained from the
egal guardian of each patient.
From September 2003 to April 2005, a total of 69 patients were
nrolled in the study. Inclusion criteria were elective congenital
eart surgery requiring CPB and weight between 5 and 10 kg.
xclusion criteria were urgent or emergency surgery, previous
eart surgery, documented coagulation disorders, use of anticoag-
lant or antiplatelet drugs within 48 hours of surgery, and proce-
ures requiring a return to CPB (2 or more CPB runs). The patients
ere then randomly assigned by drawing sealed envelopes that
ontained cards for the following groups: control, unmodified
ediatric tubing and oxygenator (COBE Cardiovascular); PMEA,
oly-2-methoxyethylacrylate coated tubing and oxygenator circuit
Terumo); SMART, phosphorylcholine-coated, polycaprolactone-
olydimethylsiloxilane additive tubing and oxygenator circuit
SMARxT Biocompatible Circuit; COBE Cardiovascular).
The same uncoated arterial and venous cannulas were used for
ll three groups. The patient weight range was selected to allow the
se of the pediatric (non-neonatal) circuit and oxygenator from
ach company. Although the anesthesia and intensive care unit
eams were blinded to patient group, it was impossible to fully
lind the operating surgeon because of the obvious differences
etween the circuits with regard to tubing texture and thickness.
Thirty-five patients were screened for the study and considered
o be candidates but were not enrolled for the following reasons:
arents refused consent (n  12), logistic issues (insufficient
quipment to perform two simultaneous studies or personnel un-
vailable, n  11), patient enrolled in a conflicting research study
n  4), non–English-speaking family with no translator available
ABLE 1. Patient demographic characteristics
Standard (n  22)
ex (male/female) 11:11
ge (mo) 7 (3-32)
eight (kg) 6.5 (5.1-9.5)
ody surface area (m2) 0.36 (0.31-0.47)
Abbreviations and Acronyms
-TG  -thromboglobulin
CPB  cardiopulmonary bypass
SM-CPB surface-modified cardiopulmonary bypassll data except sex represent median and range.
76 The Journal of Thoracic and Cardiovascular Surgery ● Septeor consent (n  3), and surgery added to the schedule late,
recluding preparation of randomized circuit (n  5).
PB Technique
fter routine anesthetic induction and orotracheal intubation, all
atients received a bolus of heparin (400 U/kg), with subsequent
oses titrated to maintain an activated clotting time longer than
80 seconds during CPB. The CPB pump prime for these circuits
as 550 mL and consisted of the following: heparin (2000 units),
odium bicarbonate (25 mEq), albumin (25%, 50 mL), mannitol
1 g/kg), and packed red blood cells calculated to provide an
n-pump hematocrit of 30%. The aorta and either the right atrial
ppendage or both vena cavae were cannulated, depending on the
perative procedure. Packed red blood cells were administered
uring the procedure to maintain a hematocrit at or above 30%
uring CPB. After weaning from CPB, modified venovenous ul-
rafiltration was performed for as long as 10 minutes at the dis-
retion of the operating surgeon. After modified ultrafiltration, or
fter weaning from CPB if ultrafiltration was not used, the heparin
as reversed with protamine sulfate (4 mg/kg). The activated
lotting time was then checked to confirm a return to baseline. The
emaining CPB pump volume was then passed through a cell-
ashing system and transfused within 2 hours of the patient’s
rrival at the intensive care unit.
lood Sample Collection and Assays
lood samples (7 mL) were drawn at five time points: baseline
after anesthesia induction), on CPB (5 minutes after institution of
PB), end CPB (after complete rewarming but before weaning
rom CPB), post-CPB (5 minutes after administration of prota-
ine), postoperative day 1 (drawn on the morning after surgery).
he samples were divided for the following assays: complete
lood cell count (hemoglobin, hematocrit, platelet count),
-thromboglobulin (-TG) level (enzyme-linked immunosorbent
ssay; Diagnostico Stago, Asnieres, France), and thromboelastog-
aphy with and without abciximab (Reopro; Centocor, Malvern,
a), performed for the four intraoperative time points but not on
ostoperative day 1. Blood samples were drawn from the indwell-
ng arterial line after aspiration of 5 mL to clear the line of heparin
nd were handled as follows: the sample for CBC was placed in a
otassium–ethylenediaminetetraacetic acid tube; the -TG sample
as placed in an iced citrate, theophylline, adenosine, and dipy-
idamole tube and centrifuged at 4°C at 2000g for 30 minutes, the
lasma supernatant was then frozen at 70°C until analysis; and
hromboelastographic assays were run immediately as described in
he following section.
MEA (n  24) SMART (n  23) P value
15:9 14:9 .65
5 (3-17) 6 (3-19) .04
6.0 (5.2-9.0) 6.0 (5.0-9.3) .4
.35 (0.31-0.45) 0.35 (0.30-0.47) .36P
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Dhromboelastography
hromboelastography without abciximab was performed by mix-
ng 350 L whole blood with 10 L 1% tissue factor in preheated
isposable cups of a Thromboelastograph Coagulation Analyzer
Haemoscope Corp, Skokie, Ill). Thromboelastography with ab-
iximab was performed by mixing 330 L whole blood with
0 L 1% tissue factor, 5 L abciximab (2 mg/mL), and 20 L
.2-mol/L calcium chloride. The thromboelastographic tracing was
hen begun and allowed to run for at least 60 minutes after the
aximum amplitude had been achieved. Two thromboelasto-
raphic values were manually measured and recorded by a single
linded author (B.E.M.): maximum amplitude values (the steady-
tate maximum amplitude of the thromboelastogram in millime-
ers, a measure of clot strength) and R values (measured from the
eginning of the elastographic trace until an amplitude of 2 mm is
chieved, a measure of rapidity of clotting). Thromboelastography
ithout abciximab represents the clotting ability of whole blood,
ncluding platelet and fibrinogen contributions. When abciximab is
dded to the reaction mixture, the platelets are inactivated, and the
hromboelastographic data is indicative of the fibrinogen contribu-
ion to clotting only.
linical Data
ntraoperative data collected included the procedure performed,
otal CPB time, aortic crossclamp time, and lowest temperature
uring CPB. Postoperative chest tube drainage, blood product use,
entilator time, and hospital stay were also recorded.
tatistical Analysis
he primary analysis of the data was performed according to
riginal treatment assignment (an intention-to-treat analysis).
ABLE 2. Cardiac diagnoses
Standard PMEA SMART
trial septal defect 5 1 2
entricular septal defect 8 11 9
etralogy of Fallot 2 5 4
omplete atrioventricular
canal defect
6 5 3
ther 1 2 5
ll data represent numbers of patients.
ABLE 3. Perioperative data
S
PB time (min) 76
ortic crossclamp time (min) 48
hest tube output in first 12 h (mL/kg) 16
inimum temperature on CPB (°C) 30
acked red blood cells transfused in first 12 h after
surgery (mL/kg)
0
latelet transfusion in first 12 h (mL/kg) 0
ime to extubation (h) 17
ospital stay (d) 4ata reported as median and range.
The Journal of Thoracicaseline characteristics were compared between treatment groups
ith the Kruskal-Wallis test for continuous variables and with the
2 or Fisher exact test for proportions. Repeated-measures analy-
es for platelet count, -TG (natural log), and thromboelastographic
utcomes (maximum amplitude with and without abciximab, R
alue with and without abciximab, natural log) were analyzed with
means model with SAS Proc Mixed (version 8; SAS Institute, Inc,
ary, NC), providing separate estimates of the means by time on
tudy (baseline, on CPB, end CPB, off CPB, and postoperative day 1)
nd treatment group. An unstructured variance-covariance form
mong the repeated measurements was assumed for each outcome,
nd estimates of the standard errors of parameters were used to
erform statistical tests and construct 95% confidence intervals.
he model-based means are unbiased with unbalanced and missing
ata, so long as the missing data are noninformative (missing at
andom). Statistical tests were 2-sided.
esults
atient demographic data are summarized in Table 1. 
hough there were no differences between groups with re-
ard to gender distribution, weight, or body surface area, the
atients randomly assigned to the control circuit were
lightly older than the patients in the PMEA and SMART
roups (median 7 [range 3-32] months vs 5 [range 3-17]
onths and 6 [range 3-20] months, respectively, P  .04).
he procedures performed and perioperative data are sum-
arized in Tables 2 and 3. All patients underwent first
ardiac surgical procedures typical for children in the 5- to
0-kg weight range, with most undergoing one of four
rocedures (atrial or ventricular septal defect closure, tetral-
gy of Fallot repair, or complete atrioventricular canal de-
ect repair). There were no significant differences between
roups for any of the perioperative variables, including CPB
ime, aortic crossclamp time, minimum temperature during
PB, postoperative chest tube drainage, blood product use,
ime to extubation, and hospital stay.
latelet Number, Activation, and Function
here were no significant differences between groups with
egard to platelet counts or -TG levels (Figure 1). Plate
rd PMEA SMART P value
75) 78 (32-134) 69 (32-121) .55
6) 46 (0-87) 35 (0-80) .22
) 15 (7-35) 18 (8-44) .28
4) 30 (24-34) 30 (24-34) .9
) 0 (0-13) 0 (0-15) .28
) 0 (0-25) 0 (0-21) .79
) 20 (5-97) 14 (8-73) .63
4 (2-11) 4 (2-12) .11tanda
(23-1
(0-13
(4-37
(26-3
(0-23
(0-17
(6-52
(2-6)and Cardiovascular Surgery ● Volume 132, Number 3 677
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Dounts decreased dramatically in all groups on initiation of
PB, with comparable levels of recovery by the following day.
Thromboelastographic results are shown in Figures
nd 3. There were no significant differences betw
roups with regard to maximum amplitude (clot strength;
igure 2), but the R value at the off CPB time 
ithout abciximab was significantly lower in the control
roup than in both the SMART (P .006) and PMEA (P
02) groups (Figure 3, A) . This would suggest that the en
oagulation system, including platelet function, was able to
orm clot more rapidly in the control patients than in the study
roup patients after weaning from CPB.
iscussion
he role of the CPB circuit in the development of postop-
rative morbidity and mortality has been the subject of
igure 1. Serial changes in mean platelet counts (A) and mean
-TG levels (B) through course of study by treatment group.
ertical bars indicate 95% confidence intervals for mean. Model-
ased means and 95% confidence intervals for -TG are reported
rom back transformation of log values to usual arithmetic scale.
OD, Postoperative day.ntensive research since the inception of mechanically as- l
78 The Journal of Thoracic and Cardiovascular Surgery ● Septent
isted cardiac surgery. Progressive advancements in perfu-
ion technology and techniques have played a major role in
ncrementally improving surgical outcomes. One area of
esearch has been the blood–artificial surface interface
ithin the CPB circuit. The first intensively studied CPB
ircuit surface modification was the heparin-coated circuit,
hich was found to decrease complement activation and
mprove clinical parameters in both children and adults7-9
Subsequent innovations have included modification of
he polymer resin during manufacture, coating the inner
urface of the tubing and oxygenators with additives after
hey have been manufactured, and a combination of these
trategies. Two of the SM-CPB circuits that have been
ested in the adult population are the PMEA X-coated
ircuit (Terumo Corp) and the SMARxT Biocompatible
ircuit (COBE Cardiovascular).3-6,10,11 Both these circuit
ave been shown to decrease complement activation, plate-
igure 2. Serial changes in mean thromboelastographic results.
aximum amplitude without (A) and with (B) abciximab. Vertical
ars indicate 95% confidence intervals for mean. POD, Postoper-
tive day.et activation and deposition, and fibrinolysis in adult car-
mber 2006
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Diac surgical patients; however, the clinical significance of
hese changes has been contradictory. Gu and colleagu10
ested the SMART circuit in a pilot study involving 20
atients randomly assigned to either uncoated or SMART
or elective coronary artery bypass grafting. The only dif-
erence they found between groups was decreased deposi-
ion of platelets within the SMART circuits, and this did not
esult in any difference between the groups with regard to
latelet counts, -TG levels, or postoperative bleeding. In a
imilar study, Sudkamp and colleagues12 evaluated the
MART circuit in 122 patients undergoing coronary artery
ypass grafting and found slightly improved platelet func-
ion in the SMART group but no difference in platelet counts
r postoperative bleeding. Defraigne and colleague s , 4 on the
ther hand, performed a nearly identical study in 100 pa-
ients undergoing coronary artery bypass grafting and found
igure 3. Serial changes in mean thromboelastographic results. R
alue without (A) and with (B) abciximab. Vertical bars indicate
5% confidence intervals for mean. Model-based means and 95%
onfidence intervals for R value are reported from back transfor-
ation of log values to usual arithmetic scale. POD, Postopera-
ive day.hat patients in the SMART circuit group had significantly r
The Journal of Thoracicigher platelet counts, lower -TG levels, a trend toward
ecreased postoperative bleeding, and significantly less
ostoperative use of fresh-frozen plasma and platelet
ransfusions.
There are very few data concerning the efficacy of these
M-CPB circuits in children, but because the ratio of the
nternal surface area of the CPB circuit to blood volume is
igher in children, one would expect the clinical advantages
f these circuits documented in adults to translate to the
ediatric population. Unfortunately, the results of this ran-
omized trial do not support this expectation. We found no
ignificant improvements in the SM-CPB circuit groups
ith regard to platelet counts, -TG levels, postoperative
leeding, or blood product use. There were no differences
etween groups by thromboelastography other than a minor
ifference in the R value after CPB, which actually favored
he control group. It should be noted that this study tested
he efficacy of SM-CPB circuits in isolation, a circumstance
n which they did not result in any significant improvements
n this patient population. These circuits theoretically could,
owever, provide an incremental improvement if used in
onjunction with other modalities, such as the routine use of
ntifibrinolytic agents, steroids, or modified ultrafiltration.
e did not assess different combinations of potential
nterventions.
These data must be considered in light of the limitations
f the study. Despite the randomization protocol, the pa-
ients in the control circuit group were slightly older than
he study group patients. The effect of this minor age
ifference is unclear, because the weights of the patients and
iagnoses were comparable, but it must be considered. Also,
emodilution had a major impact on platelet counts in this
atient population, as would be expected, and this degree of
emodilution could have overwhelmed any improvement
esulting from the SM-CPB circuits. However, the fact that
he -TG levels were the same among groups suggests that
latelet activation was comparable among groups, and until
ommercially available CPB circuits are miniaturized to a
reater degree, hemodilution will remain a clinical reality
hat must be considered in any clinically relevant study for
hildren. Regarding postoperative transfusions, the decision
o transfuse was made in collaboration with the intensive
are unit team, which was blinded to study group; however,
he operating surgeons, who were not entirely blinded, were
lso involved in the decision to transfuse, so the potential
or selection bias did exist. Several other limitations include
he limited scope of the platelet functional assays, which
ay have missed subtle changes in platelet function, and the
atient population selected for the study. This study inten-
ionally excluded complex neonatal cases to increase the
omogeneity of the patient population and limit diagnosis-
elated variability as much as possible.
and Cardiovascular Surgery ● Volume 132, Number 3 679
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DIn conclusion, this randomized trial demonstrated no
ignificant advantages for the SM-CPB circuits relative to
n uncoated circuit in elective pediatric cardiac surgery. The
M-CPB circuits did not significantly decrease platelet ac-
ivation, improve platelet function, or improve postopera-
ive outcomes. This study suggests that the advantages of
M-CPB circuits demonstrated in the adult population may
ot translate to the pediatric population.
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